Keywords: cj, corp, nexmed, femprox, marketing, deal, south

CJ Corp and NexMed in FemProx marketing deal

Article | 29 March 2004

Print This

South Korea's CJ Corp has secured the licence for NexMed's Femprox (alprostadil), a cream treatment for female sexual arousal disorder, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in